预约演示
更新于：2024-12-06
Hydrochlorothiazide/Telmisartan
替米沙坦氢氯噻嗪
更新于：2024-12-06
概要
基本信息
药物类型 小分子化药 |
别名 Telmisartan and Hydrochlorothiazide、TELMISARTAN/HYDROCHLOROTHIAZIDE、Telmisartan/Hydrochlorothiazide + [14] |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂) |
治疗领域 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-11-17), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C40H38ClN7O6S2 |
InChIKeyOZCVMXDGSSXWFT-UHFFFAOYSA-N |
CAS号485391-74-0 |
关联
49
项与 替米沙坦氢氯噻嗪 相关的临床试验CTR20242468
替米沙坦氢氯噻嗪片（40 mg/12.5 mg）在健康受试者中空腹/餐后生物等效性试验
CTIS2023-504812-13-00
Effects of single-pill combination of telmisartan/amlodipine and telmisartan/amlodipine/hydrochlorothiazide on 24-hour blood pressure (BP) reduction, 24-h BP variability and office BP control in patients with arterial hypertension – SATELLITE - KCT02/2023-SATELLITE
CTR20231329
替米沙坦氢氯噻嗪片在中国成年健康受试者中的一项随机、开放、空腹和餐后单次给药、两制剂、三序列、三周期交叉的生物等效性研究
100 项与 替米沙坦氢氯噻嗪 相关的临床结果
登录后查看更多信息
100 项与 替米沙坦氢氯噻嗪 相关的转化医学
登录后查看更多信息
100 项与 替米沙坦氢氯噻嗪 相关的专利（医药）
登录后查看更多信息
4
项与 替米沙坦氢氯噻嗪 相关的文献（医药）2012-09-01Journal of the renin-angiotensin-aldosterone system : JRAAS4区 · 医学
Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension
4区 · 医学
ArticleOA
作者: Shimizu, Tomohiko ; Kuwano, Takashi ; Mitsutake, Ryoko ; Shiga, Yuhei ; Saku, Keijiro ; Nagata, Itsuki ; Shirotani, Tetsuro ; Fujisawa, Kazuaki ; Miura, Shin-ichiro ; Uehara, Yoshinari ; Norimatsu, Kenji ; Inoue, Asao ; Arimura, Tadaaki ; Matsunaga, Eiyu ; Morii, Joji
Objective::
Many patients still have high blood pressure (BP) after treatment with high-dose angiotensin II type 1 receptor blockers (ARBs) or Preminent® (medium-dose of losartan (50 mg/day)/hydrochlorothiazide (HCTZ) (12.5 mg/day)). Therefore, we analyzed whether Micombi®BP (high-dose telmisartan (80 mg/day)/HCTZ (12.5 mg/day)) could provide better results with regard to efficacy and safety for patients with uncontrolled hypertension.
Methods::
In total, 44 hypertensive patients (22 males, age 71±14 years) who showed uncontrolled BP despite the use of high-dose ARBs or Preminent® were enrolled in this study. We used a changeover design in which the patients were switched from high-dose ARBs or Preminent® to Micombi®BP. We analyzed BP, heart rate (HR), and biochemical parameters before and after treatment for 3 months.
Results::
Systolic BP and diastolic BP significantly decreased (125±15/69±11 mmHg) and 85% of the patients achieved their target BP at 3 months after changeover. Patients who switched from ARBs and those who switched from Preminent® showed similar BP-lowering effects. In addition, the reductions in BP after 3 months in patients with or without chronic kidney disease and in those with or without metabolic syndrome (MetS) were also similar. There were no significant changes in HR during the study period. Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects.
Conclusion::
High-dose telmisartan/HCTZ therapy was associated with a significant reduction in BP and helped patients achieve their target BP.
2008-01-01Drugs1区 · 医学
Telmisartan/Hydrochlorothiazide
1区 · 医学
Review
作者: White, William B. ; Plosker, Greg L.
Fixed-dose combinations of telmisartan and hydrochlorothiazide (HCTZ) [Micardis Plus, Micardis HCT, PritorPlus] are available in many countries for the treatment of patients with essential hypertension. Combining the angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) telmisartan with the thiazide diuretic HCTZ provides antihypertensive therapy with complementary mechanisms of action. In the US and EU, telmisartan/HCTZ is approved for patients whose hypertension is not adequately controlled with telmisartan monotherapy; US labelling for the fixed-dose combination also includes inadequate control of blood pressure (BP) with HCTZ monotherapy.The antihypertensive efficacy of once-daily telmisartan/HCTZ has been demonstrated in several large, randomized trials in patients with stages 1 and 2 hypertension. The addition of HCTZ to telmisartan achieved significant reductions in BP in nonresponders to telmisartan monotherapy, and the antihypertensive efficacy of telmisartan/HCTZ was similar to or significantly greater than that of various comparator agents. Moreover, in studies that used ambulatory BP monitoring, telmisartan/HCTZ provided consistent 24-hour BP reductions throughout morning, daytime and night-time periods. The BP-lowering efficacy over the entire 24-hour dose administration interval is consistent with the pharmacokinetic profile of telmisartan, which has the longest elimination half-life among currently available ARBs and a unique chemical structure. Adverse events with telmisartan/HCTZ in clinical trials were typically mild and transient, and no unexpected events occurred that had not been previously reported with either telmisartan or HCTZ. Extensive tolerability data are available for telmisartan, in particular from the ONTARGET study, the largest clinical outcomes trial with an ARB. As such, fixed-dose combinations of telmisartan/HCTZ provide an effective, rational and generally well tolerated treatment option for the management of patients with hypertension.
2003-09-01Revue medicale de Liege
[Kinzalkomb, a fixed telmisartan-hydrochlorothiazide combination for the treatment of hypertension].
Review
作者: Kulbertus, H
Kinzalkomb marketed in Belgium by Bayer is a fixed combination of telmisartan 80 mg and hydrochlorothiazide 125 mg for the treatment of hypertension. New guidelines for the treatment of hypertension were recently released both in Europe and the United States (see article by J.M. Krzesinski in this issue). They offer the choice of using a fixed biotherapy even as first line treatment. Hydrochlorothiazide at low dose is a frequent component of such biotherapies: it is efficacious and secure. Telmisartan is a highly selective blocker of angiotensin II AT1 receptors ("sartans"); it is at least as effective as the classical antihypertensive agents; thanks to its half-life, the longest of all sartans', it provides adequate antihypertensive coverage throughout the whole 24-hour postdose interval and particularly over the last 6 hours of the dosage interval. Its tolerability profile is equivalent to placebo. The combination telmisartan-hydrochlorothiazide is more effective than each agent alone at lowering blood pressure; furthermore telmisartan possesses a potassium-sparing effect that when the two drugs are coadministered attenuates the kaliuretic effect of hydrochlorothiazide. Various large trials are currently under way (ONTARGET, TRANSCEND, PROFESS, PROTECTION, DETAIL). These studies which together involve some 50,000 patients will hopefully help to further specify the role of telmisartan in condition which require an intervention on the renin-angiotensin system.
100 项与 替米沙坦氢氯噻嗪 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 欧盟 | 2002-04-19 | |
| 原发性高血压 | 欧盟 | 2002-04-19 | |
| 原发性高血压 | 冰岛 | 2002-04-19 | |
| 原发性高血压 | 冰岛 | 2002-04-19 | |
| 原发性高血压 | 列支敦士登 | 2002-04-19 | |
| 原发性高血压 | 列支敦士登 | 2002-04-19 | |
| 原发性高血压 | 挪威 | 2002-04-19 | |
| 原发性高血压 | 挪威 | 2002-04-19 | |
| 高血压 | 美国 | 2000-11-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 132 | (Telmisartan + HCTZ + Amlodipine) | 鬱襯選膚簾積憲膚淵簾(鑰衊構鑰膚夢餘糧顧顧) = 網壓壓願膚夢鹽選鹹醖 憲憲獵蓋壓鬱鹽餘積醖 (醖積繭淵製鏇齋淵願積, 顧鏇襯憲壓窪獵選憲廠 ~ 餘選製獵簾窪蓋築築夢) 更多 | - | 2016-03-28 | ||
placebo+telmisartan + HCTZ (Telmisartan + HCTZ + Placebo) | 鬱襯選膚簾積憲膚淵簾(鑰衊構鑰膚夢餘糧顧顧) = 鹹遞簾廠積鑰繭觸積餘 憲憲獵蓋壓鬱鹽餘積醖 (醖積繭淵製鏇齋淵願積, 夢淵遞願醖鏇壓壓顧壓 ~ 憲齋願觸簾襯憲鬱齋製) 更多 | ||||||
临床3期 | - | 639 | 壓鏇觸淵鏇鹹鑰壓齋鏇(鑰製齋憲廠艱鏇窪觸醖) = occurred in 29 (4.5%) patients 製夢網製鑰選觸壓築製 (壓構願鬱簾觸網觸積繭 ) | - | 2009-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用